Regeneron Pharmaceuticals Inc. played up the potential for building a franchise around wet AMD drug Eylea, including new indications and co-formulations, after reporting better-than-expected fourth-quarter sales.
In a preliminary report on the fourth quarter, the company reported Jan. 14 that Eylea (aflibercept) posted U.S. sales of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?